Pfizer Corporation

Raqualia Pharma Inc.

Naomi Ueno

Seiji Nukui

Yoshiyuki Okumura

Kazunari Nakao

Akiyoshi Kawai

Tomoki Kato

Kana Taniguchi

Yoshinobu Hashizume

Miyako Matsumizu

Yoriko Miyake

Katsuhiro Shinjyo

This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y, Y, Yand Yare independently selected from N, CH, etc.; Ris H, Calkyl, etc.; Qis a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is Calkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; Ris H, Calkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, Calkyl, etc.; m is 0, 1 or 2; Rand Rare independently selected from H and Calkyl ; Ris H, Calkyl, etc.; Qis a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamadin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y, Y, Yand Yare independently selected from N, CH, etc.; Ris H, Calkyl, etc.; Qis a 5&#x2013;12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5&#x2013;6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is Calkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; Ris H, Calkyl, etc.; Z is a 5&#x2013;12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, Calkyl, etc.; m is 0, 1 or 2; Rand Rare independently selected from H and Calkyl; Ris H, Calkyl, etc.; Qis a 5&#x2013;12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

Growing community of inventors

Aichi-ken, Japan

Naomi Ueno